Covered recipient · General Payments record
JENNIFER LYNN NASH
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$1,665.20
83 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,593.20 | 82 |
| Education | $72.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $591.89 | 28 |
| Janssen Biotech, Inc. | $208.03 | 9 |
| Lilly USA, LLC | $141.76 | 2 |
| PFIZER INC. | $138.50 | 16 |
| E.R. Squibb & Sons, L.L.C. | $88.51 | 5 |
| Galderma Laboratories, L.P. | $69.84 | 4 |
| GENZYME CORPORATION | $61.69 | 2 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $59.54 | 3 |
| UCB, Inc. | $49.96 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $48.51 | 2 |
| Organon LLC | $28.79 | 2 |
| Almirall LLC | $26.68 | 1 |
| MAYNE PHARMA COMMERCIAL LLC | $25.34 | 1 |
| Novartis Pharmaceuticals Corporation | $23.45 | 1 |
| Arcutis Biotherapeutics, Inc. | $22.06 | 1 |
| Botanix SB Inc | $21.81 | 1 |
| Incyte Corporation | $21.51 | 1 |
| Regeneron Healthcare Solutions, Inc. | $20.54 | 1 |
| KYOWA KIRIN, INC. | $16.79 | 1 |
Page 1 of 2; records 1–50 of 83 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JENNIFER LYNN NASH
NPI 1518924299 · CMS profile ID 341673
Allopathic & Osteopathic Physicians / Dermatology
WESTERVILLE, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 83 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518924299?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JENNIFER LYNN NASH, NPI 1518924299, CMS profile ID 341673. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 83 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518924299?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JENNIFER LYNN NASH, NPI 1518924299, CMS profile ID 341673. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 83 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518924299?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JENNIFER LYNN NASH, NPI 1518924299, CMS profile ID 341673, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 83 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1518924299?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
83 matching records · $1,665.20 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 83.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $3.36 | 12/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229900139 | CMS |
| Janssen Biotech, Inc. | $18.98 | 12/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174388415 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $25.06 | 12/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251009523 | CMS |
| ABBVIE INC. | $28.52 | 11/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239279 | CMS |
| Botanix SB Inc | $21.81 | 11/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246263929 | CMS |
| GENZYME CORPORATION | $29.44 | 11/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233315810 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $17.98 | 11/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251009521 | CMS |
| Organon LLC | $14.91 | 11/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237727394 | CMS |
| Janssen Biotech, Inc. | $25.01 | 11/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174386944 | CMS |
| Janssen Biotech, Inc. | $15.92 | 10/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174387737 | CMS |
| PFIZER INC. | $4.66 | 10/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229830973 | CMS |
| Janssen Biotech, Inc. | $21.32 | 10/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174387803 | CMS |
| GENZYME CORPORATION | $32.25 | 10/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233315802 | CMS |
| PFIZER INC. | $16.52 | 10/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229451566 | CMS |
| ABBVIE INC. | $18.63 | 09/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239268 | CMS |
| ABBVIE INC. | $156.39 | 09/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239274 | CMS |
| ABBVIE INC. | $24.10 | 09/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239262 | CMS |
| PFIZER INC. | $3.94 | 09/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229144676 | CMS |
| UCB, Inc. | $22.83 | 09/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224533695 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $25.34 | 09/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1254270233 | CMS |
| PFIZER INC. | $3.90 | 09/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229186226 | CMS |
| PFIZER INC. | $17.31 | 09/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229271091 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.17 | 08/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184556066 | CMS |
| KYOWA KIRIN, INC. | $16.79 | 08/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222098056 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $16.50 | 08/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251009519 | CMS |
| ABBVIE INC. | $15.36 | 08/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239256 | CMS |
| ABBVIE INC. | $13.32 | 08/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239250 | CMS |
| PFIZER INC. | $15.73 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229181132 | CMS |
| Janssen Biotech, Inc. | $1.00 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174386446 | CMS |
| Janssen Biotech, Inc. | $14.67 | 07/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174386784 | CMS |
| ABBVIE INC. | $8.55 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239244 | CMS |
| ABBVIE INC. | $20.12 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239238 | CMS |
| PFIZER INC. | $5.67 | 07/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228918716 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.14 | 07/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184556056 | CMS |
| Galderma Laboratories, L.P. | $17.22 | 07/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234682687 | CMS |
| PFIZER INC. | $4.72 | 07/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228804871 | CMS |
| Organon LLC | $13.88 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237727392 | CMS |
| ABBVIE INC. | $12.53 | 07/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239231 | CMS |
| ABBVIE INC. | $18.32 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239225 | CMS |
| Galderma Laboratories, L.P. | $15.39 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234682685 | CMS |
| PFIZER INC. | $4.51 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1230073292 | CMS |
| ABBVIE INC. | $17.43 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239219 | CMS |
| ABBVIE INC. | $15.66 | 06/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239214 | CMS |
| Regeneron Healthcare Solutions, Inc. | $20.54 | 06/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212997885 | CMS |
| ABBVIE INC. | $19.42 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239209 | CMS |
| PFIZER INC. | $20.47 | 06/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228805613 | CMS |
| ABBVIE INC. | $17.85 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239203 | CMS |
| ABBVIE INC. | $20.70 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1203239196 | CMS |
| Janssen Biotech, Inc. | $72.00 | 05/09/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174386328 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.40 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184556016 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $243,014.48 | 48 |
| PY2024 | Recipient | $1,267.72 | 7 |
| PY2024 | Principal investigator | $137,527.38 | 8 |
| PY2023 | Principal investigator | $787,642.30 | 65 |
| PY2022 | Recipient | $187.10 | 4 |
| PY2022 | Principal investigator | $974,316.67 | 62 |
| PY2021 | Recipient | $890.12 | 6 |
| PY2021 | Principal investigator | $503,922.68 | 30 |
| PY2020 | Principal investigator | $730,035.42 | 59 |
| PY2019 | Principal investigator | $647,335.59 | 32 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
65 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $132.00 | 12/31/2023 | Non-covered Recipient Entity AVENTIV RESEARCH DUBLIN | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998414255 |
| Principal investigator 1 | ABBVIE INC. | $3,006.00 | 12/31/2023 | Non-covered Recipient Entity AVENTIV RESEARCH DUBLIN | This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL. | No dispute reported | 06/30/2026 | 998414257 |
| Principal investigator 1 | ABBVIE INC. | $77.25 | 12/31/2023 | Non-covered Recipient Entity AVENTIV RESEARCH DUBLIN | This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to severe GL. | No dispute reported | 06/30/2026 | 998414259 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 11/30/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998409189 |
| Principal investigator 1 | ABBVIE INC. | $2,106.20 | 10/05/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998402769 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 09/08/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998399053 |
| Principal investigator 1 | ABBVIE INC. | $742.50 | 09/08/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998399077 |
| Principal investigator 1 | ABBVIE INC. | $2,824.50 | 08/31/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998397449 |
| Principal investigator 1 | ABBVIE INC. | $9,000.00 | 08/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | Multicenter, Double-Blind, Randomized, Placebo-controlled, Dose-Ranging Phase 2 Active Comparator Study Evaluating the Efficacy and Safety of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines | No dispute reported | 06/30/2026 | 998393893 |
| Principal investigator 1 | ABBVIE INC. | $7,698.50 | 08/03/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998393287 |
| Principal investigator 1 | ABBVIE INC. | $1,822.50 | 07/27/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998392671 |
| Principal investigator 1 | ABBVIE INC. | $1,400.00 | 07/27/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998392677 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 07/27/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998392693 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 07/18/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence | No dispute reported | 06/30/2026 | 998391835 |
| Principal investigator 1 | ABBVIE INC. | $1,309.50 | 07/18/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998391837 |
| Principal investigator 1 | ABBVIE INC. | $742.50 | 07/12/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998390669 |
| Principal investigator 1 | ABBVIE INC. | $5,143.50 | 07/12/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998390671 |
| Principal investigator 1 | ABBVIE INC. | $6,673.75 | 07/06/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998389807 |
| Principal investigator 1 | ABBVIE INC. | $158.51 | 06/07/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence | No dispute reported | 06/30/2026 | 998385437 |
| Principal investigator 1 | ABBVIE INC. | $7,224.65 | 06/01/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998384915 |
| Principal investigator 1 | ABBVIE INC. | $5,400.00 | 05/30/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998384683 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 05/30/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence | No dispute reported | 06/30/2026 | 998384689 |
| Principal investigator 1 | ABBVIE INC. | $29.61 | 05/30/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998384711 |
| Principal investigator 1 | ABBVIE INC. | $420.00 | 05/30/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998384745 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 05/30/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998384755 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 05/24/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998384383 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 05/24/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998384389 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 05/24/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998384391 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 05/24/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998384395 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 05/24/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998384397 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 05/24/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998384399 |
| Principal investigator 1 | ABBVIE INC. | $688.50 | 05/04/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998380521 |
| Principal investigator 1 | ABBVIE INC. | $8,855.85 | 05/04/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998380705 |
| Principal investigator 1 | ABBVIE INC. | $7,927.78 | 05/04/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998380919 |
| Principal investigator 1 | ABBVIE INC. | $5,232.50 | 05/04/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998380921 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 04/27/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998379663 |
| Principal investigator 1 | ABBVIE INC. | $1,800.00 | 04/27/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998379665 |
| Principal investigator 1 | ABBVIE INC. | $162.00 | 04/12/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998377591 |
| Principal investigator 1 | ABBVIE INC. | $237.60 | 04/12/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998377593 |
| Principal investigator 1 | ABBVIE INC. | $2,511.00 | 04/06/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998377301 |
| Principal investigator 1 | ABBVIE INC. | $16,706.86 | 04/05/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998376541 |
| Principal investigator 1 | ABBVIE INC. | $14,204.85 | 03/30/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998375971 |
| Principal investigator 1 | ABBVIE INC. | $37,716.46 | 03/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998373341 |
| Principal investigator 1 | ABBVIE INC. | $17,690.95 | 03/02/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998372143 |
| Principal investigator 1 | ABBVIE INC. | $1,655.10 | 03/02/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence | No dispute reported | 06/30/2026 | 998372177 |
| Principal investigator 1 | ABBVIE INC. | $121.50 | 02/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998369047 |
| Principal investigator 1 | ABBVIE INC. | $40.50 | 02/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence | No dispute reported | 06/30/2026 | 998370279 |
| Principal investigator 1 | ABBVIE INC. | $71,178.44 | 02/02/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998368011 |
| Principal investigator 1 | ABBVIE INC. | $19,548.65 | 02/02/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998368743 |
| Principal investigator 1 | ABBVIE INC. | $1,890.20 | 02/02/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence | No dispute reported | 06/30/2026 | 998368745 |
| Principal investigator 1 | ABBVIE INC. | $121.50 | 01/18/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998366721 |
| Principal investigator 1 | ABBVIE INC. | $2,470.50 | 01/18/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998366811 |
| Principal investigator 1 | ABBVIE INC. | $9,791.25 | 01/11/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364643 |
| Principal investigator 1 | ABBVIE INC. | $95,676.12 | 01/11/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364645 |
| Principal investigator 1 | ABBVIE INC. | $18,351.20 | 01/11/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence | No dispute reported | 06/30/2026 | 998365425 |
| Principal investigator 1 | ABBVIE INC. | $4,579.70 | 01/11/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence | No dispute reported | 06/30/2026 | 998365443 |
| Principal investigator 1 | ABBVIE INC. | $534.60 | 01/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364449 |
| Principal investigator 1 | ABBVIE INC. | $34,595.25 | 01/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364451 |
| Principal investigator 1 | ABBVIE INC. | $47,976.75 | 01/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364453 |
| Principal investigator 1 | ABBVIE INC. | $7,500.00 | 01/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | No dispute reported | 06/30/2026 | 998364463 |
| Principal investigator 1 | ABBVIE INC. | $66,412.92 | 01/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364465 |
| Principal investigator 1 | ABBVIE INC. | $82,141.70 | 01/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364467 |
| Principal investigator 1 | ABBVIE INC. | $132,708.10 | 01/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364469 |
| Principal investigator 1 | ABBVIE INC. | $405.00 | 01/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364471 |
| Principal investigator 1 | ABBVIE INC. | $1,095.00 | 01/09/2023 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines | No dispute reported | 06/30/2026 | 998364473 |